Zobrazeno 1 - 10
of 114
pro vyhledávání: '"Arlene S. Swern"'
Autor:
Sundar Jagannath, Yi Lin, Hartmut Goldschmidt, Donna Reece, Ajay Nooka, Alicia Senin, Paula Rodriguez-Otero, Ray Powles, Kosei Matsue, Nina Shah, Larry D. Anderson, Matthew Streetly, Kimberly Wilson, Hoa Van Le, Arlene S. Swern, Amit Agarwal, David S. Siegel
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 6, Pp 1-9 (2021)
Abstract Patients with relapsed and refractory multiple myeloma (RRMM) who are triple-class exposed (to an immunomodulatory agent, proteasome inhibitor, and anti-CD38 antibody) have limited treatment options and there is no standard of care. Idecabta
Externí odkaz:
https://doaj.org/article/2da165d00d0f46f59b7b9f3b9d2490cc
Autor:
Jeff P. Sharman, Kim Cocks, Chadi Nabhan, Nicole Lamanna, Neil E. Kay, David L. Grinblatt, Christopher R. Flowers, Matthew S. Davids, Pavel Kiselev, Arlene S. Swern, Kristen Sullivan, Mecide M. Gharibo, E. Dawn Flick, Andrew Trigg, Anthony Mato
Publikováno v:
eJHaem, Vol 1, Iss 1, Pp 188-198 (2020)
Abstract Health‐related quality of life (HRQoL) in patients with chronic lymphocytic leukemia (CLL) is important in guiding treatment decisions. However, the impact of CLL treatment initiation on HRQoL is unclear. We assessed HRQoL using the FACT
Externí odkaz:
https://doaj.org/article/34c06b8e749f4507ab23a49de144c417
Autor:
Daniel A. Pollyea, Tracy I. George, Mehrdad Abedi, Rafael Bejar, Christopher R. Cogle, Kathryn Foucar, Guillermo Garcia‐Manero, David L. Grinblatt, Rami S. Komrokji, Jaroslaw P. Maciejewski, Dennis A. Revicki, Gail J. Roboz, Michael R. Savona, Bart L. Scott, Mikkael A. Sekeres, Michael A. Thompson, Sandra E. Kurtin, Chrystal U. Louis, Melissa Nifenecker, E. Dawn Flick, Arlene S. Swern, Pavel Kiselev, David P. Steensma, Harry P. Erba
Publikováno v:
eJHaem, Vol 1, Iss 1, Pp 58-68 (2020)
Abstract Diagnostic and molecular genetic testing are key in advancing the treatment of acute myeloid leukemia (AML), yet little is known about testing patterns outside of clinical trials, especially in older patients. We analyzed diagnostic and mole
Externí odkaz:
https://doaj.org/article/b36efed85da84efcbaf5ae149d394d44
Autor:
Inhye E. Ahn, Charles M. Farber, Matthew S. Davids, David L. Grinblatt, Neil E. Kay, Nicole Lamanna, Anthony Mato, Chadi Nabhan, Pavel Kiselev, Arlene S. Swern, E. Dawn Flick, Kristen Sullivan, Jeff P. Sharman, Christopher R. Flowers
Publikováno v:
Blood Advances, Vol 1, Iss 25, Pp 2433-2443 (2017)
Abstract: Chemoimmunotherapy for chronic lymphocytic leukemia (CLL) promotes clonal evolution of aggressive clones, which in some patients may lead to early progression of disease (POD). We studied the prognostic value of early POD in a cohort of pat
Externí odkaz:
https://doaj.org/article/f151c5319e37462ba900987b62bc8361
Autor:
Lisa Pleyer, Hartmut Döhner, Hervé Dombret, John F. Seymour, Andre C. Schuh, CL Beach, Arlene S. Swern, Sonja Burgstaller, Reinhard Stauder, Michael Girschikofsky, Heinz Sill, Konstantin Schlick, Josef Thaler, Britta Halter, Sigrid Machherndl Spandl, Armin Zebisch, Angelika Pichler, Michael Pfeilstöcker, Eva M. Autzinger, Alois Lang, Klaus Geissler, Daniela Voskova, Wolfgang R. Sperr, Sabine Hojas, Inga M. Rogulj, Johannes Andel, Richard Greil
Publikováno v:
International Journal of Molecular Sciences, Vol 18, Iss 2, p 415 (2017)
We recently published a clinically-meaningful improvement in median overall survival (OS) for patients with acute myeloid leukaemia (AML), >30% bone marrow (BM) blasts and white blood cell (WBC) count ≤15 G/L, treated with front-line azacitidine ve
Externí odkaz:
https://doaj.org/article/4b9d62725e1a4be8848eda86bb48a909
Autor:
Steven D. Gore, Pierre Fenaux, Valeria Santini, John M. Bennett, Lewis R. Silverman, John F. Seymour, Eva Hellström-Lindberg, Arlene S. Swern, Charles. L. Beach, Alan. F. List
Publikováno v:
Haematologica, Vol 98, Iss 7 (2013)
The phase III AZA-001 study established that azacitidine significantly improves overall survival compared with conventional care regimens (hazard ratio 0.58 [95% confidence interval 0.43–0.77], P
Externí odkaz:
https://doaj.org/article/6508cf69c75041979b3ba8331d78d2f5
Autor:
Arlene S. Swern, Michael R. Savona, Rami S. Komrokji, David L. Grinblatt, Dennis A. Revicki, Guillermo Garcia-Manero, Melissa Nifenecker, Jaroslaw P. Maciejewski, Pavel Kiselev, Mehrdad Abedi, Bart L. Scott, David P. Steensma, Elizabeth Dawn Flick, Chrystal U. Louis, Christopher R. Cogle, Michael A. Thompson, Jay Patel, Gail J. Roboz, Kathryn Foucar, Harry P. Erba, Mikkael A. Sekeres, Tracy I. George, Daniel A. Pollyea, Sandra E. Kurtin
Publikováno v:
International Journal of Laboratory Hematology
Introduction The presence of ring sideroblasts (RS) and mutation of the SF3B1 gene are diagnostic of lower‐risk (LR) myelodysplastic syndromes (MDS) and are correlated with favorable outcomes. However, information on testing and reporting in commun
Autor:
Arlene S. Swern, Chadi Nabhan, E. Dawn Flick, David L. Grinblatt, Christopher R. Flowers, Neil E. Kay, Kim Cocks, Anthony R. Mato, Nicole Lamanna, Kristen A. Sullivan, Matthew S. Davids, Andrew Trigg, Pavel Kiselev, Mecide Gharibo, Jeff P. Sharman
Publikováno v:
eJHaem. 1:188-198
Autor:
Arlene S. Swern, Chrystal U. Louis, Christopher R. Cogle, E. Dawn Flick, David L. Grinblatt, Dennis A. Revicki, Guillermo Garcia-Manero, Michael R. Savona, Tracy I. George, Bart L. Scott, Michael A. Thompson, David P. Steensma, Kathryn Foucar, Mehrdad Abedi, Daniel A. Pollyea, Sandra E. Kurtin, Melissa Nifenecker, Gail J. Roboz, Jaroslaw P. Maciejewski, Mikkael A. Sekeres, Pavel Kiselev, Rami S. Komrokji, Harry P. Erba, Rafael Bejar
Publikováno v:
eJHaem. 1:58-68
Autor:
E. Dawn Flick, Jeff P. Sharman, Neil E. Kay, David L. Grinblatt, Charles M. Farber, Kristen A. Sullivan, Anthony R. Mato, Sarah M. Gressett Ussery, Mecide Gharibo, Christopher R. Flowers, Arlene S. Swern, Chadi Nabhan, Nicole Lamanna, Matthew S. Davids, Pavel Kiselev
Publikováno v:
Blood Advances. 4:1407-1418
Optimal treatment of chronic lymphocytic leukemia (CLL) remains unclear. The Connect CLL Registry, a United States–based multicenter prospective observational cohort study, enrolled 1494 patients between 2010 and 2014 from predominantly community-b